J Pediatric Infect Dis Soc


. 2023 Mar 17;piac124.
doi: 10.1093/jpids/piac124. Online ahead of print.
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study


Gilad Sherman 1 2 , Gabriella S Lamb 1 2 , Tanvi S Sharma 1 2 , Elizabeth C Lloyd 3 , Jerod Nagel 4 , Nada N Dandam 4 , Carlos R Oliveira 5 , Hassan S Sheikha 5 , Brenda I Anosike 6 , Philip Lee 6 , Surabhi B Vora 7 , Karisma Patel 8 , Paul K Sue 8 , Beenish Rubbab 8 , April M Yarbrough 9 , Lakshmi Ganapathi 1 2 , Mari M Nakamura 1 2 10



Affiliations

Abstract

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.